We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Supply@me Capital Plc | LSE:SYME | London | Ordinary Share | GB00BFMDJC60 | ORD 0.002P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00005 | 1.14% | 0.00445 | 0.004 | 0.0049 | 0.0054 | 0.005 | 0.01 | 152,152,399 | 16:35:29 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Prepackaged Software | 842k | -4.35M | -0.0001 | 0.00 | 3.16M |
Date | Subject | Author | Discuss |
---|---|---|---|
12/9/2020 22:47 | Nobby.. Prof Stephen Evans, Professor of Pharmacoepidemiology “It is sad that stock market rules seem to militate against proper scientific release of at least a preprint of a scientific paper. It is also not clear whether a data monitoring committee was involved in advising release of the data publicly. The adage that says “BEWARE OF SMALL STUDIES CLAIMING LARGE BENEFITS” should be borne in mind here. There are reasons to believe it could well be an effective treatment, but these results, while encouraging, should not be taken to mean that the treatment is so dramatic that everyone should be given it. There is a need for many more patients to be recruited and for any adverse effects to be carefully evaluated. Thrombotic microangiopathy was a rare but SEVERE COAGULATION PROBLEM associated with an injectable form of the drug, and, given the COAGULATION PROBLEMS associated with COVID-19, great care will be needed to ensure that such problems do not occur with the inhaled form of the drug.” I assume this information never made it into your SNG group. | eggy toast | |
12/9/2020 22:13 | No, it isn't 'nonsense' Nobby. I'm in SNG & have been quite a while, way before the 400% rise. FACTS remain, even if you don't like them. I hope approval is given to SNG001 & any doubts over blood coagulation issue are cleared up. I'm in ODX too. I feel a whole lot more confident in SYME, but that's a personal judgement, one you too are free to make. | eggy toast | |
12/9/2020 21:23 | Sound advice here my man | stccpins | |
12/9/2020 20:48 | It's one to buy, tuck away in an ISA and forget about for a year at least. It's difficult with all the pending news and potential not to think about and keep checking this one. | yabawbag | |
12/9/2020 20:29 | >> egg toast Complete and utter nonsense. SNG001 has a very clean safety profile with no issues seen so far. And at least one approval and drug order is about to arrive IMHO so although the price rise has been very impressive already you ain't seen nothing yet. I expect at least another 3 fold shortly..... In the short term it is a way better bet than SYME IMHO! | nobbygnome | |
12/9/2020 20:08 | Nobbygnome's favourite SNG rose from 4.6 to 250 this year & for what? The potential of an unproven drug helping with COVID which may yet be proven useless regarding treatment of COVID patients as interferon can cause blood clots. A real problem as COVID is known to cause blood clots. ODX has gone from around 7 to a peak of 90 on what? Antibody testing, which may yet be proven pretty useless with regard to COVID. I imagine SYME will surely see an extremely fast rise at some point in the near future. | eggy toast | |
12/9/2020 20:06 | How many shares have you go if you don't mind me asking sir | stccpins | |
12/9/2020 20:05 | Exactly why I'm in mate. 3k now could be 300k if everything falls into place and it takes off. Imagen kicking yourself in a few years for a small investment now... Fingers crossed | stccpins | |
12/9/2020 19:54 | True, I believe that to be a short to medium term comment, I believe he'll have some sort of exit plan.£1 or so in 5 years might not be out of range. Who knows though the model hasn't been tried and tested, the next 4-6 weeks are huge for the business.Someone previously made the point Amazon, Mastercard, Apple all started small with huge doubters so we need to start somewhere. Look at Ronald Wayne, if he'd only held on! | yabawbag | |
12/9/2020 19:50 | £1 is a most excellent thought. I'd be extremely happy with a quarter of that price (& will certainly never work again). | eggy toast | |
12/9/2020 19:34 | Az has said under no circumstances will he sell his shares. But we shall see I mean I think we would all be laughing to the bank if we could get £1 a share ? | stccpins | |
12/9/2020 19:15 | I think everyone will add big on first sign off of big funding.. Nln | still waiting | |
12/9/2020 19:13 | Even with 3k invested at 100p that would be 320k for me,That will do nicely ? | countdracula55 | |
12/9/2020 19:11 | dw....you are not alone lol. | countdracula55 | |
12/9/2020 19:10 | Not thought that far ahead, I'd suggest the majority shareholders may have been bought out by the 5 year mark. Depends what AZs exit strategy.I'll take a stab at a range of 90p-£1 in 5 years from now. | yabawbag | |
12/9/2020 19:09 | Lol...you've not learned to hide them yet then. | countdracula55 | |
12/9/2020 19:04 | Count I might need to try that one, if I could get a crumpet in this house! | yabawbag | |
12/9/2020 19:00 | Just add marmite and a thin slice of cheddar. | countdracula55 | |
12/9/2020 18:57 | Eggy the cranberry and stilton does sound good | yabawbag | |
12/9/2020 18:54 | Never tried anything other than butter on a toasted crumpet,Need to adventure out a bit! | yabawbag | |
12/9/2020 18:28 | What does everyone think a price could be 3-5 years from now I've got like 1million shares. Nothing massive I know considering people have brought 30 plus million in one go ? I'm in at like 0.490 for my million | stccpins | |
12/9/2020 15:41 | Once of a day I'd have been happy with a just a bit of crumpet. | different world | |
12/9/2020 15:13 | Crumpets ,with melted Cheese and cayenne pepper... | ccr1958 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions